Status Equity Research Initiates Coverage of Oncovista Innovative Therapies, Inc. (OVIT.OB) - Long Term Target Price $16.00

Share Article

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

Oncovista Innovative Therapies, Inc. (OTCBB: OVIT.OB) is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics.

According to the Status Equity Research report published August 12, 2008, the world market for in vitro diagnostic (IVD) tests for cancer is growing at 11% annually and could reach $8 billion by the end of 2012.

Status concludes that a successful market launch and penetration of OVIT's AdnaTest, can yield $80 million in first year, post launch sales in the U.S. in 2010.

The research report can be accessed at http://statusequity.com/uploads/ONCOVISTA_INC_-_FULL_REPORT_-_080808.pdf

Other active stocks are Johnson & Johnson (NYSE: JNJ); Novartis AG (NYSE: NVS); Sanofi-Aventis (NYSE: SNY).

For More Information on Oncovista Innovative Therapies, Inc. please visit: http://www.oncovista.com.

For More Information on Status Equity Research please visit: http://www.statusequity.com.

About Status Equity Research

Status Equity Research is a monthly publication committed to providing coverage on unique emerging growth companies that can become sector leaders in the U.S. equity markets.

About OncoVista, Inc.

OncoVista is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies both through the acquisition of rights to technologies and drugs from others and through the development of proprietary products. OncoVista focuses on candidates that have been previously tested in human clinical trials or animal models, as well as technologies that may improve the delivery or targeting of previously tested, and in some cases marketed, anticancer agents.

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire $2,495.00 for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation do no trading of any kind and send No Faxes or emails.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

WB

516-942-4910
Email >
Visit website